Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zentalis Pharmaceuticals (ZNTL) Total Liabilities (2022 - 2025)

Historic Total Liabilities for Zentalis Pharmaceuticals (ZNTL) over the last 4 years, with Q3 2025 value amounting to $74.4 million.

  • Zentalis Pharmaceuticals' Total Liabilities fell 2279.04% to $74.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $74.4 million, marking a year-over-year decrease of 2279.04%. This contributed to the annual value of $93.2 million for FY2024, which is 1850.09% down from last year.
  • Zentalis Pharmaceuticals' Total Liabilities amounted to $74.4 million in Q3 2025, which was down 2279.04% from $77.2 million recorded in Q2 2025.
  • Over the past 5 years, Zentalis Pharmaceuticals' Total Liabilities peaked at $114.3 million during Q4 2023, and registered a low of $74.4 million during Q3 2025.
  • Over the past 4 years, Zentalis Pharmaceuticals' median Total Liabilities value was $98.2 million (recorded in 2023), while the average stood at $96.6 million.
  • As far as peak fluctuations go, Zentalis Pharmaceuticals' Total Liabilities soared by 1518.26% in 2023, and later plummeted by 2922.76% in 2025.
  • Quarter analysis of 4 years shows Zentalis Pharmaceuticals' Total Liabilities stood at $105.3 million in 2022, then increased by 8.56% to $114.3 million in 2023, then fell by 18.5% to $93.2 million in 2024, then decreased by 20.16% to $74.4 million in 2025.
  • Its last three reported values are $74.4 million in Q3 2025, $77.2 million for Q2 2025, and $88.6 million during Q1 2025.